Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) EBITDA Margin (2020 - 2024)

Fulcrum Therapeutics (FULC) has disclosed EBITDA Margin for 4 consecutive years, with 3615.28% as the latest value for Q3 2023.

  • On a quarterly basis, EBITDA Margin changed N/A to 3615.28% in Q3 2023 year-over-year; TTM through Mar 2025 was 106.58%, a 453868.0% increase, with the full-year FY2024 number at 11.82%, up 343466.0% from a year prior.
  • EBITDA Margin was 3615.28% for Q3 2023 at Fulcrum Therapeutics, up from 9471.19% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 355.0% in Q1 2021 to a low of 9471.19% in Q1 2023.
  • A 4-year average of 1859.32% and a median of 902.3% in 2020 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: surged 211233bps in 2021, then crashed -844414bps in 2023.
  • Fulcrum Therapeutics' EBITDA Margin stood at 420.19% in 2020, then fell by -12bps to 470.42% in 2021, then plummeted by -285bps to 1809.14% in 2022, then tumbled by -100bps to 3615.28% in 2023.
  • Per Business Quant, the three most recent readings for FULC's EBITDA Margin are 3615.28% (Q3 2023), 9471.19% (Q1 2023), and 1809.14% (Q2 2022).